Immunotherapeutic targets in non-small cell lung cancer.

Sadeghirad, H; Bahrami, T; Layeghi, SM; Yousefi, H; Rezaei, M; Hosseini-Fard, SR; Radfar, P; Warkiani, ME; O'Byrne, K; Kulasinghe, A

Immunotherapeutic targets in non-small cell lung cancer.

Sadeghirad, H Bahrami, T Layeghi, SM Yousefi, H Rezaei, M Hosseini-Fard, SR Radfar, P Warkiani, ME O'Byrne, K Kulasinghe, A

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Immunology, 2023, 168, (2), pp. 256-272
Issue Date:: 2023-02

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.62 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Sadeghirad, H
dc.contributor.author	Bahrami, T
dc.contributor.author	Layeghi, SM
dc.contributor.author	Yousefi, H
dc.contributor.author	Rezaei, M
dc.contributor.author	Hosseini-Fard, SR
dc.contributor.author	Radfar, P
dc.contributor.author	Warkiani, ME
dc.contributor.author	O'Byrne, K
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2023-03-14T23:16:47Z
dc.date.available	2022-08-02
dc.date.available	2023-03-14T23:16:47Z
dc.date.issued	2023-02
dc.identifier.citation	Immunology, 2023, 168, (2), pp. 256-272
dc.identifier.issn	0019-2805
dc.identifier.issn	1365-2567
dc.identifier.uri	http://hdl.handle.net/10453/167332
dc.description.abstract	Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Immunology
dc.relation.isbasedon	10.1111/imm.13562
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1107 Immunology, 1114 Paediatrics and Reproductive Medicine
dc.subject.classification	Immunology
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Endothelial Cells
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Endothelial Cells
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Endothelial Cells
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Tumor Microenvironment
dc.title	Immunotherapeutic targets in non-small cell lung cancer.
dc.type	Journal Article
utslib.citation.volume	168
utslib.location.activity	England
utslib.for	1107 Immunology
utslib.for	1114 Paediatrics and Reproductive Medicine
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-03-14T23:16:45Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	168
utslib.citation.issue	2

Abstract:

Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/167332